Many drugmakers last year fell victim to COVID-19 related FDA inspection delays that stalled drug approvals, and GlaxoSmithKline’s oncology hopeful dostarlimab was not immune, the British Big Pharma has revealed.  Approval for the drug—picked up…

Politicians of all stripes have run on promises to lower drug prices over the years, and outgoing President Donald Trump was no different. Fast-forward four years—past several attempts to rein in drug…

The Nasdaq Biotechnology Index has risen more than 600% in the last 15 years, reflecting investor enthusiasm for a flood of novel drugs that Wall Street analysts pegged as likely…

Bayer and partner Merck & Co. have carried a new heart failure drug across the FDA finish line, hoping to carve blockbuster share out of an ever-more-competitive field. As industry…

Fresenius Kabi’s manufacturing hiccups multiplied as 2020 unfolded. Now, a little more than a week into the new year, the German drugmaker found its way onto the FDA’s recall list…

The first DTC ad campaign for Viatris and Theravance’s COPD nebulizer therapy Yupelri aims to show the freedom of the once-daily treatment. In a newly debuted TV ad, an older woman celebrates her birthday with a…

Pfizer has returned the commercial rights to topical pain drug Flector to its original developer. The developer, IBSA Pharma, said it has lowered the price of Flector to make it…

Samsung Biologics was among a handful of manufacturers to enjoy a production boost during the COVID-19 pandemic. Now, as work on a “Super Plant” in its native South Korea progresses,…